AACC and DxPx Debut Start-Up City Pavilion
|AACC and DxPx, an Industry & Investor Conference on Diagnostics, Digital Health, Precision Medicine, and Life Science Tools, are partnering to bring an international conference to the Clinical Lab Expo floor. The DxPx Industry and Investor Partnering Conference, Startup City Pavilion, facilitates licensing, financing, co-development, and M&A opportunities.
The Startup City Pavilion, located at the back of the Clinical Lab Expo, will feature the products and services of pre-qualified companies. In addition, a series of panel discussions, fireside chats, and vetted product pitches will be featured in the DxPx Conference Theatre. DxPx Conference attendees will receive a free Expo Only pass.
Alertgy has developed DeepGluco®, a wearable Non- Invasive Continuous Blood Glucose Monitor (NICBGM) sensor that can fit on smartwatch and report via apps. For more information, visit https://www.alertgy.com/
Allergios is an ingeniously effective and scalable in vitro allergy diagnostic that works by visualising the allergic response. We recently closed a seed financing round (oversubscribed) which is proof of the ongoing support for our innovation, and which will enable us to take our development to the clinical trial stage, currently planned for the first half of 2023 - for which we will raise a next financing round. At DxPx/AACC we’d like to discuss partnering with you. Allergios – We see Allergy.
Avisa is a clinical-stage medical device company developing the Avisa BreathTest™, a novel drug/device biomarker technology platform that enables the ultra-rapid detection of virulent bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its drug substrates via proprietary delivery systems. The Company has established clinical proof-of-concept through trials in cystic fibrosis, tuberculosis and community-acquired pneumonia, which demonstrated positive safety and clinical efficacy results. Avisa is planning pivotal trials in Post-COVID-19 bronchiectasis and ventilator-associated pneumonia and plans to submit Investigational Device Exemption applications to the U.S. FDA for these trials next year.
About the company: DxLab Inc. (DxLab) is a venture-backed biotech startup, spun out of MIT and Harvard, developing and commercializing next-generation point-of-care (POC) diagnostic systems for rapid and low-cost detection of various pathogens. Combining proprietary platform technology with novel target detection and signal processing methods, we are advancing a pipeline of rapid POC tests for different pathogens and biomarkers.
What is your product, service, or innovation? We have developed a new diagnostic solution, which we call the DxHub. The DxHub is a small toaster-sized device (only weighing 5.1 lb.) that can test up to eight individual samples in a random-access manner (which is the highest sample handling capacity among currently available POC testing devices). We have also developed a rapid and accurate COVID-19 test that runs on the DxHub. This testing system (DxHub + COVID-19 test) received the emergency use authorization (EUA) from the FDA, and we are currently seeking additional clearance from other regulatory agencies in different countries. Importantly, our diagnostic assay is built on a technology that is very flexible and adaptable, allowing us to develop and distribute new tests for other pathogens and conditions at an extremely rapid pace.
How will it impact the field of lab medicine, diagnostics, life science, healthcare, etc.? POC testing for the presence of dangerous pathogens is highly valuable as it can lead to prompt and effective countermeasures against the pathogens, enabling preparation for and prevention of a spread instead of slow reaction after the outbreak had already occurred. In the case of highly contagious diseases, such as COVID-19 and other emerging zoonotic diseases, widespread, high-volume testing is critically needed for an effective public health response. Our solution uniquely enables high-throughput testing at the POC, which is extremely valuable for various use settings that are currently relying on central laboratories for high-volume testing, removing delays and logistical hurdles related to sample shipping and results sharing. In addition, our testing solution can create new use cases that will greatly benefit from rapid high-throughput testing at the POC, such as testing at the last-mile locations for war fighters or other service personnel to protect them from the dangerous pathogens. Our product can thus help bring high-quality, high-volume testing outside of central laboratories for rapid and effective control of dangerous pathogens wherever it is needed most, making all of us safer.
|About Patti White
Patti White is a serial entrepreneur who has devoted her career to commercializing technology that can make a difference in people’s lives. Patti and her cofounder, Peter Galen, each have over 25 years’ experience in medical technology, together have launched over 60 medical products globally, and have had multiple successful exits. Hemex Health represents their fourth time working together.
About Hemex Health
Hemex Health designs diagnostic platforms to meet the needs of fast-growing, decentralized, global point-of-care markets. Our Gazelle™ diagnostic device is rugged, easy to use, and includes miniaturized technologies that support tests with gold-standard accuracy for a variety of metabolic and infectious diseases. Our unique design philosophy allows us to price affordably for large markets while maintaining profitable margins.
About the company: HyliDx is a team of IVD veterans developing the industry’s first connected platform for home-monitoring of multiple blood-based biomarkers for chronic disease. Combined with secure cloud connectivity, AI, and physician oversight, the HyliDx remote monitoring and care platform will first be applied to kidney disease—to improve patient outcomes while reducing the costs of treatment and hospitalization by $100B in the US alone.
What is your product, service, or innovation? We’ve developed optical sensing for comprehensive testing of fingerprick blood samples, allowing cost-effective and accessible remote monitoring for many biomarkers and burdensome chronic diseases beyond diabetes. Our first target is chronic kidney disease (CKD)—with a patient population size and medical costs similar to diabetes (120M patients in the US and Europe, costing more than $400B), but no players in remote monitoring.
How will it impact the field of lab medicine, diagnostics, life science, healthcare, etc.? Given the right investment, and with the only comprehensive platform for remote care of CKD, HyliDx could become a vertically-integrated ‘Livongo of CKD’. Our platform will provide frequent, on-demand testing to many non-diabetic, chronic-disease patients for the first time. This will allow early detection and more effective treatment of acute complications while, in the long term, giving patients feedback they need to fully engage in their therapy and lifestyle changes, improving outcomes. With our HyliDx eHealth results-tracking and patient-doctor communications app, patients will also gain peace of mind from far more doctor oversight and feedback, at far reduced cost. All results from our blood testing instrument will be transmitted via the app to our AI-enabled HyliDx cloud—with detection algorithms and alerts for abnormal levels or trends—then on to the patient’s electronic medical record. Doctors can review test results and alerts, and send therapy updates to the patient on the app, at any time and without the need for an appointment—either in-person or virtual. This will free doctors’ valuable time and keep patients out of emergency rooms and expensive hospital beds, except when they’re absolutely needed. In the case of CKD, HyliDx will measure the biomarkers most associated with disease progression and hospitalization—such as potassium (which, when elevated by disease or medication, can cause cardiac arrhythmia)—with the ultimate goal of slowing progression towards life-altering and highly expensive kidney failure.
About the company: InfanDx is a privately held IVD company with a focus on novel diagnostic solutions for neonatal acute and critical care. The Company’s proprietary lead product in clinical development is the InfanDx HypoxE® Test designed for the reliable diagnosis of Hypoxic-Ischemic Encephalopathy (HIE) within the first hours of life supporting clinicians in the timely decision on the initiation of neuroprotective therapies. For more information, please visit: http://www.infandx.com/
What is your product, service, or innovation? InfanDx HypoxE® Test (in Clinical Development)
How will it impact the field of lab medicine, diagnostics, life science, healthcare, etc.? The Company’s proprietary lead product in clinical development is the InfanDx HypoxE® Test designed for the reliable identification of hypoxic-ischemic encephalopathy (HIE) within the first hours of life. HIE as a consequence of perinatal asphyxia (oxygen deficit during birth) can result in life-long disabilities. The long-term detrimental effects of HIE can be mitigated and even prevented by neuroprotective hypothermia treatment. However, this therapy must be initiated within six hours after birth to be effective, requiring suitable diagnostic methods to reliably and timely identify the affected newborns. While standard-of-care diagnostic methods cannot deliver a conclusive diagnosis of HIE within this time frame, the rapid InfanDx HypoxE® Test is designed to support clinicians in the timely decision whether newborns require neuroprotective hypothermia treatment.
The demonstrated breakthrough sensitivity of Kaya17’s fluorescent immunoassay platform addresses a major unmet medical need for accurate and sensitive point of care diagnosis in primary care settings, saving payers and labs money and providing greater confidence for critical healthcare decisions in infectious diseases, allergy, cancer and women's health. The Kaya17 test process is similar to a direct ELISA, but gives more sensitive results (can detect lower levels of protein in sample), is less expensive and easier to setup and use. The COVID19 saliva based antigen test has a throughput of 30-50 saliva samples/hour/instrument and having achieved a breakthrough sensitivity that is similar to PCR.
The KAYA17 point-of-care test is a 15-minute Rapid test for COVID-19, which is perfectly adaptable for testing individuals, as well as small or large groups of people. The testing may be done infrequently or on a regular, periodic basis. It can also be done quickly, accurately, and inexpensively. KAYA17's proprietary software makes the workflow, and the initial data gathering to electronic delivery of the final results, simple in various testing scenarios
About the company: Lino Biotech AG, a Swiss based technology spin-out from Roche and ETH Zurich, is the world’s only company specialized in focal Molography – an entirely new method for measuring molecular interactions in living cells or crude biological samples. The broadly patented technology offers cost-effective label-free detection assays while eliminating signal disturbances due to temperature changes or non-specific binding. The entirely new method of measuring molecular interactions enables customers from cell and gene therapy to optimize their R&D and production processes, reduce cost, and improve product quality while at the same time the technology offers new applications in bioprocessing, diagnostics, and precision medicine.
What is your product, service, or innovation? Focal molography is a nanotechnology-based method that cleverly combines photolithography, molecular self-assembly and state-of-the-art optical technology. It is a truly interdisciplinary technology, inspired by physics, tailored for biology and implemented for biomolecular interaction analysis.
Nostics is developing an instant diagnostics platform. Their test kits will allow for rapid testing (few minutes), anywhere in the world, without expensive and time-consuming lab facilities. Starting with SARS-CoV-2 (COVID-19) other test will follow. By applying nanotechnology, photonics and machine learning, Nostics brings a new type of diagnostics to a world desperately in need for 21st century solutions.
Prenosis is a health tech innovator devoted to ushering in a new era of precision diagnostics in acute care using artificial intelligence. Its ImmunixTM precision diagnostics platform leverages machine learning algorithms trained on deep biological data and broad clinical data designed to capture and illuminate the complex health states of patients more holistically. Its proprietary NOSISTM dataset is one of the largest and fastest-growing hybrid biomarker-clinical datasets for sepsis care. The Sepsis ImmunoScoreTM diagnostic on the ImmunixTM platform has the potential to save thousands of lives and billions of dollars in healthcare spending annually. The Sepsis ImmunoScoreTM is not yet approved for commercial use in the United States.
About the company: At RevealDx we use AI to mine the largest source of healthcare data on the planet: medical images. Our flagship product helps clinicians diagnose lung cancer earlier by using patented techniques to identify highly suspicious lung nodules before an interval scan.
What is your product, service, or innovation? RevealAI-Lung is a software solution that integrates directly into a radiologist's PACS making our software available with a single mouse click.
How will it impact the field of lab medicine, diagnostics, life science, healthcare, etc.? Clinical studies show that we can identify nearly half of all cancerous nodules before an interval scan.
Protein profiling plays an essential part in today’s biomedical research, striving to improve patients’ quality of life by using molecular signatures for diagnosis and treatment guidance.
At Sciomics, we believe that our explorative proteomic and post-translational modification profiling platform enables true progress in precision medicine. Our unique antibody microarray platform reduces costs and attrition rates in protein biomarker identification and verification projects. Thereby, we were able to establish a broad biomarker development pipeline for oncological indications as well as organ failure. Our protein biomarker signatures aim at a precise and detailed diagnosis for patient stratification in order to adapt the therapy exactly to the patient needs. To improve the situation in the current pandemics, we are working on the development of protein biomarkers for an early stratification of patients which will suffer from a severe COVID-19 disease.
Surfix Diagnostics works on a new biosensor technology, the photonic biosensor.
This ultra-sensitive, fast and label-free technology harbours the possibility of detecting multiple biomarkers at the same time. Features that, along with a potentially low unit cost and the ability to easily scale up production, will revolutionize the world of medical diagnostics by enabling PoC diagnosis and treatment monitoring of a wide variety of conditions.
The plug-and-play platform consists of a photonic (to simplify it could be compared with how glass fibre optics) biochip and a microfluidic cartridge (Lab-on-a-Chip) with a desktop reader (with reads the photonic signal). The system can be used in the lab, but also closer to the patient like in the ER, the ICU, the doctor’s office or any other place close to the patient (Point of Care or Point of Need).
The system is not limited to use in the human medical field, but can also be adapted to use in other application areas like veterinary, food and feed, agriculture, aquaculture etc.
The company was founded as a spin-off from the department of Organic Chemistry of Wageningen University & Research and has been very successful as a provider of R&D services in the field of nanocoatings for biosensors and microfluidic devices.
The company now focuses on the development and marketing of its photonic diagnostics platform.
About the company: WindyCitySDR, teaming up with Drexel University's Theoretical & Applied Mechanics Group, manufactures wideband software defined radios which allows for creating complete wireless communications systems entirely in software unlike our existing "Hardware Radios" such as your TV, AM/FM radios, and/or Magnetic Resonance Imaging machine you can't "Software Upgrade" to the "Next New Thing". Example: A "hardware radio", such as a 4G LTE Smartphone, can't be "Software Upgraded" to a 5G Smartphone but with a "software defined radio", you can easily switch between 4G & 5G, just by changing your software.
What is your product, service, or innovation? Software Defined Radio "Open" MRI system
How will it impact the field of lab medicine, diagnostics, life science, healthcare, etc.? A Software Defined Radio "Open" MRI system enables the medical staff of hospitals & clinics the ability to create/customize their MRI systems to their liking, I.E., being able to 3-D print both "gradient & receiver coils" enables more innovation while lowering the costs of acquiring them as these are usually designed & manufactured by "traditional hardware MRI manufacturers" at very expensive pricing. Additionally, since most "traditional hardware MRI systems" utilize Helium as a coolant, a scarce costly resource, software defined radios eliminates this as we're able to utilize a full range of radio frequencies that doesn't induce radiation which increases the cost of healthcare.